Rigel Pharmaceuticals | Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Agenus USD -274.14M 80.46M 2025-09
Amgen USD 9.62B 2.19B 2025-09
Anika Therapeutics USD 146.8M 867K 2025-09
Arrowhead Research USD 568.42M 102.37M 2025-12
AstraZeneca USD 48.67B 2.78B 2025-12
BioMarin Pharmaceutical USD 6.06B 29.6M 2025-09
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Celldex Therapeutics USD 598.36M 57.04M 2025-09
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Eli Lilly USD 23.79B 5.52B 2025-09
Halozyme Therapeutics USD 503.92M 171.17M 2025-09
Heron Therapeutics USD 14.88M 42.14M 2025-09
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
Ligand Pharmaceuticals USD 950.17M 121.64M 2025-09
MacroGenics USD 67M 20.38M 2025-09
Neurocrine Biosciences USD 3B 309.3M 2025-09
Pfizer USD 92.8B 4.11B 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Veracyte USD 1.26B 36.61M 2025-09


Rigel Pharmaceuticals Capitale Sociale E Riserve - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.